Alzheimer’s Trials Face a Severe Participant Shortage

Reporting describes 158 Alzheimer’s therapies across 192 trials and an estimated 350,000 applicants needed, highlighting recruitment as a major barrier to treatment research. Public misunderstanding, screening rejection, limited trustworthy trial information, and inadequate diversity may slow progress; informed, equitable participation and better trial-navigation resources are needed. The World Alzheimer Report 2026 reinforces the importance of scientific validity and real-world applicability but adds no sufficiently detailed new finding here.